{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:54:53Z","timestamp":1792155293085,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.contraception.2010.11.002","type":"journal-article","created":{"date-parts":[[2010,12,24]],"date-time":"2010-12-24T09:19:35Z","timestamp":1293182375000},"page":"155-159","source":"Crossref","is-referenced-by-count":21,"title":["Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism"],"prefix":"10.1016","volume":"84","author":[{"given":"Fernando Augusto","family":"Barreiros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Aparecida Falbo","family":"Guazzelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Regina","family":"Torloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio F.","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2010.11.002_bb0005","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1056\/NEJM198109103051104","article-title":"Oral contraceptives and cardiovascular diseases (first of two parts)","volume":"305","author":"Stadel","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2010.11.002_bb0010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJM198109173051205","article-title":"Oral contraceptives and cardiovascular diseases (second of two parts)","volume":"305","author":"Stadel","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2010.11.002_bb0015","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/humupd\/5.6.627","article-title":"The \u201cpill scare\u201d: the responses of authorities, doctors and patients using oral contraception","volume":"5","author":"Sarewski","year":"1999","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.contraception.2010.11.002_bb0020","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/humupd\/5.6.672","article-title":"Biological coagulation findings in third-generation oral contraceptives","volume":"5","author":"Conard","year":"1999","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.contraception.2010.11.002_bb0025","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/humupd\/5.6.565","article-title":"The recent saga of cardiovascular disease and safety of oral contraceptives","volume":"5","author":"Edwards","year":"1999","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.contraception.2010.11.002_bb0030","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1056\/NEJM199011153232003","article-title":"The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism","volume":"323","author":"Godsland","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2010.11.002_bb0035","first-page":"98","article-title":"Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel","volume":"40","author":"Teichmann","year":"1995","journal-title":"Int J Fertil Menopausal Stud"},{"key":"10.1016\/j.contraception.2010.11.002_bb0040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0010-7824(99)00026-8","article-title":"Clinical comparison of triphasic norgestimate\/35 micrograms ethinyl estradiol and monophasic norethindrone acetate\/20 micrograms ethinylestradiol. Cycle control, lipid effects, and user satisfaction","volume":"59","author":"Sulak","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.11.002_bb0045","first-page":"53","article-title":"Atherosclerosis: what is it and why does it occur?","volume":"69","author":"Davies","year":"1993","journal-title":"Br Heart J"},{"key":"10.1016\/j.contraception.2010.11.002_bb0050","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0015-0282(16)45371-9","article-title":"Oral contraceptives and the decline in mortality form circulatory disease","volume":"35","author":"Wiseman","year":"1981","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2010.11.002_bb0055","first-page":"323","article-title":"Safety of oral contraceptives related to steroid content: a critical review","volume":"34","author":"Sturdevant","year":"1989","journal-title":"Int J Fertil"},{"key":"10.1016\/j.contraception.2010.11.002_bb0060","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0002-9378(85)80001-6","article-title":"Oral contraceptives and cardiovascular disease: a critique to the epidemiologic studies","volume":"152","author":"Realini","year":"1985","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 2","key":"10.1016\/j.contraception.2010.11.002_bb0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/13625187.2002.11949333","article-title":"High acceptability and satisfaction with NuvaRing use","volume":"7","author":"Szarewski","year":"2002","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"2","key":"10.1016\/j.contraception.2010.11.002_bb0070","first-page":"6","article-title":"FDA approves NuvaRing contraceptive implant","volume":"5","year":"2002","journal-title":"J Gend Specif Med"},{"key":"10.1016\/j.contraception.2010.11.002_bb0075","series-title":"Medical eligibility criteria for contraceptive use. Reproductive heath and research","author":"World Health Organization","year":"2009"},{"key":"10.1016\/j.contraception.2010.11.002_bb0080","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"10.1016\/j.contraception.2010.11.002_bb0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.contraception.2009.10.007","article-title":"Extended regimens of the contraceptive vaginal ring: evaluation of clinical aspects","volume":"81","author":"Barreiros","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.11.002_bb0090","doi-asserted-by":"crossref","first-page":"-9","DOI":"10.1016\/j.contraception.2004.01.004","article-title":"The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study","volume":"69","author":"Tuppurainen","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.11.002_bb0095","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(01)07098-2","article-title":"High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study","volume":"358","author":"Walldius","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2010.11.002_bb0100","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jacc.2007.09.060","article-title":"High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies","volume":"51","author":"van der Steeg","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.contraception.2010.11.002_bb0105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3109\/00016349409013416","article-title":"Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone","volume":"73","author":"Akerlund","year":"1994","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.contraception.2010.11.002_bb0110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2796.2003.01276.x","article-title":"Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid modifying therapy","volume":"255","author":"Walldius","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.contraception.2010.11.002_bb0115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2796.2006.01616.x","article-title":"Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person\/ten-country panel","volume":"259","author":"Barter","year":"2006","journal-title":"Intern Med"},{"key":"10.1016\/j.contraception.2010.11.002_bb0120","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(08)61076-4","article-title":"Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Comment","volume":"372","author":"McQueen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2010.11.002_bb0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/07853899509031958","article-title":"In\ufb02uence of oral contraceptive use on lipoprotein (a) and other coronary heart disease risk factors","volume":"27","author":"Porkka","year":"1995","journal-title":"Ann Med"},{"key":"10.1016\/j.contraception.2010.11.002_bb0130","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/0002-9378(88)90199-8","article-title":"Oral contraception and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins","volume":"158","author":"Crook","year":"1988","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2010.11.002_bb0135","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0010-7824(97)00010-3","article-title":"Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin","volume":"55","author":"Crook","year":"1997","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.11.002_bb0140","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.contraception.2007.08.001","article-title":"Contraceptive vaginal ring use for women has less adverse metabolic effects than an oral contraceptive","volume":"76","author":"Elkind-Hirsch","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.11.002_bb0145","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.contraception.2007.01.027","article-title":"Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen","volume":"75","author":"Sitruk-Ware","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.11.002_bb0150","first-page":"CD006133","article-title":"Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus","volume":"7","author":"Lopez","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2010.11.002_bb0155","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.contraception.2004.06.001","article-title":"Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg)","volume":"70","author":"Machado","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.11.002_bb0160","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.contraception.2009.08.009","article-title":"Effect of a continuous regimen of contraceptive combination of ethinylestradiol and drospirenone on lipid, carbohydrate and coagulation profiles","volume":"81","author":"Machado","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2010.11.002_bb0165","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.contraception.2009.07.011","article-title":"Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use","volume":"81","author":"Wiegratz","year":"2010","journal-title":"Contraception"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782410006402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782410006402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:12:50Z","timestamp":1592179970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782410006402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0010782410006402"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2010.11.002","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}